當(dāng)前位置： 首頁 - 產(chǎn)品目錄 - 小分子抑制劑
Triciribine phosphate (TCN-P,VQD-002,NSC-280594) 磷酸曲西立濱
| 貨號(hào) | IPA1014 | 售價(jià)（元） | 3618 |
| 規(guī)格 | 5mg | CAS號(hào) | 61966-08-3 |
- 產(chǎn)品簡介
- 相關(guān)產(chǎn)品
貨號(hào)
名稱
規(guī)格
價(jià)格
IPA1014-0005MG
Triciribine phosphate
5MG
3618
IPA1014-0010MG
Triciribine phosphate
10MG
6623
產(chǎn)品簡介：
磷酸曲西立濱是一種蛋白激酶B抑制劑。它有可能用于治療卵巢癌和乳腺癌。
產(chǎn)品性質(zhì)：
CAS No.：61966-08-3
別名：VQD 002, PTX200, VQD002, PTX 200, PTX-200, VQD-002
分子量：400.28
分子式：C13H17N6O7P
存儲(chǔ)：Powder: -20°C for 3 years | In solvent: -80°C for 2 years
溶解度：DMSO: Soluble( < 1 mg/mL refers to the product slightly soluble or insoluble )
注意事項(xiàng)：
為了您的安全和健康，請(qǐng)穿實(shí)驗(yàn)服并戴一次性手套操作。
Reference:
1. Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-9. doi: 10.1007/s10637-010-9479-2. PubMed PMID: 20644979; PubMed Central PMCID: PMC4612514.
2. Kim R, Yamauchi T, Husain K, Sebti S, Malafa M. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. Anticancer Res. 2015 Sep;35(9):4599-604. PubMed PMID: 26254348.
3. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov;37(11):1461-7. doi: 10.1016/j.leukres.2013.07.034. PubMed PMID: 23993427; PubMed Central PMCID: PMC4205589.
4. Moore EC, Hurlbert RB, Boss GR, Massia SP. Inhibition of two enzymes in de novo purine nucleotide synthesis by triciribine phosphate (TCN-P). Biochem Pharmacol. 1989 Nov 15;38(22):4045-51. PubMed PMID: 2480792.